Research programme: single domain antibodies - Domantis

Drug Profile

Research programme: single domain antibodies - Domantis

Alternative Names: DMS 3008

Latest Information Update: 19 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Domantis
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Autoimmune disorders; Chronic obstructive pulmonary disease; Hypersensitivity; Inflammation; Inflammatory bowel diseases; Lupus vulgaris; Multiple myeloma; Osteoarthritis; Rheumatoid arthritis; Small cell lung cancer; Solid tumours

Most Recent Events

  • 16 Apr 2008 Preclinical pharmacodynamics data presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,
  • 25 Jan 2008 Preclinical development is ongoing
  • 07 Jan 2007 Domantis has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top